BioSpace News Archive

Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease (SCD) treatment, announced today that the company’s Sideline Sickle Cell campaign, led by Emmy Award-winning NFL broadcaster Solomon Wilcots, will be participating in “Shine The Light on Sickle Cell”

Morneau Shepell Inc. (“MSI”) announced today a cash dividend of $0.065 per share for the month of June 2019, to be paid on July 16, 2019 to holders of record of shares of MSI on June 28, 2019.

Ajax Health announced today that it has raised an additional $15 million, closing out Ajax II at a total of more than $100 million.

Applied BioMath (www.appliedbiomath.com), the industry leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, is proud to welcome Helen Moore, PhD, as Director of Applied Mathematics.

Hundreds gather for largest-ever on-campus concert as artists perform their hits, take photographs, sign autographs

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development Authority (‘BARDA’) has increased the total value of its award for the clinical and regulatory development of Summit’s precision antibiotic ridinilazole for the treatment of C. difficile infection (‘CDI’) to up to $63.7 million.

Market leader in temperature-controlled microscopy, Linkam Scientific Instruments, announces the appointment of The Scott Partnership as its new partner for PR & Marketing activities. Managing Director, Louise Reid will lead the team as they take over from Talking Science & founder Jezz Leckenby, who announced his retirement earlier this year.

Be The Match BioTherapies(R), an organization offering solutions for companies developing and commercializing cell and gene therapies, and TrakCel, a software developer for cell and gene therapy supply chain tracking and orchestration systems, today announce a collaboration that will provide integrated solutions for companies developing cell and gene therapies.

Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, announced it has licensed ORM-12741 from Orion Corporation.

Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C